NeoStem, Inc. Logo
(NasdaqCM: NBS)
Enter your email to receive
the RedChip Money Report
weekly newsletter.
Money Report
Investment Highlights
  • Strong IP portfolio in rapidly growing industry
  • Proprietary cell therapy pipeline; Phase 2 AMR-001 PreSERVE trial enrollment expected to be completed with data read-out in 2013; additional assets in early-stage development
  • Revenue-generating contract manufacturing business
  • Revenue growth of 98% for continuing operations for nine months ended September 30, 2012
  • Strong management team with deep regulatory experience
  • Validation of approach through agreements with “Who’s Who” of cell therapy companies
  • Successfully completed six M&A transactions
  • Company received $12.3 million in cash and eliminated over $30 million in debt obligations through divesture of Chinese operations in November 2012
  • Ranked #1 in the Tri-State region and #7 nationally on Deloitte’s 2012 Technology Fast 500
Financial Highlights
financial Highlights
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. As an emerging technology and market-leading company in this fast-developing cell therapy industry, NeoStem’s multifaceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near- and long-term revenue growth opportunities.

According to BCC Research, the global market for stem cell products is expected to grow at nearly 12% annually, from $3.8 billion in 2011 to $6.6 billion in 2016. NeoStem has the expertise and existing research capabilities and collaborators to enable it to achieve its mission of becoming a premier cell therapy company. The Company’s service business and pipeline of proprietary cell therapy products work in concert, giving the Company a competitive advantage that is unique in the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a significant intellectual property estate, NeoStem is poised for substantial valuation improvement.
Stock Chart and Summary
Recent News
©2014 RedChip Companies, Inc. | "Discovering Tomorrow’s Blue Chips Today." ™ | Disclaimer | Disclosures | Policies